苯二氮平類類藥物市場 - 按產品、藥物類別、適應症、給藥途徑、配銷通路、全球預測 2024 - 2032 年

Benzodiazepine Drugs Market - By Product, Drug Class, Indication, Route of Administration, Distribution Channel, Global Forecast 2024 - 2032

出版日期: 2024年03月08日 | 出版商:

Global Market Insights Inc. | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於焦慮症病例增加、對心理健康問題的認知不斷提高以及老年人口不斷擴大，苯二氮平類類藥物市場預計在 2024 年至 2032 年期間複合年成長率為 3.9%。

據世界衛生組織稱，目前世界上大約 4% 的人口受到焦慮症的影響。在全球範圍內，焦慮症的發生率增加，包括恐慌症和社交焦慮症等疾病。盛行率激增歸因於多種因素，包括社會壓力、經濟不確定性和生活方式的改變。隨著人們尋求有效的治療方案來控制症狀和改善生活品質，對以其抗焦慮特性而聞名的苯二氮平類藥物的需求持續上升。此外，苯二氮平類藥物作為治療焦慮症的第一線藥物干預措施的出現進一步促進了其廣泛使用，推動了製藥業的市場成長。

苯二氮平類類藥物產業根據產品、藥物類別、適應症、給藥途徑、配銷通路和地區進行分類。

由於地西泮的抗焦慮、鎮靜和肌肉鬆弛特性及其在治療焦慮症、肌肉痙攣和酒精戒斷症狀中的應用，地西泮細分市場將在 2032 年實現健康成長。其治療各種病症的多功能性、有效性和相對較低的成本為其贏得了巨大的市場佔有率。此外，學名藥的出現進一步推動了地西泮的採用。

由於高壓力水平、生活方式的改變和人口老化，到 2032 年，失眠領域將在苯二氮平類藥物市場佔據相當大的佔有率。苯二氮平類藥物，包括地西泮和其他衍生物，如替馬西泮和勞拉西泮，由於其鎮靜催眠特性，通常用於短期治療失眠。然而，對其潛在的依賴性和不良反應的擔憂導致了更嚴格的審查和對替代治療方式的探索。

在龐大的人口基礎、精神健康疾病盛行率上升以及醫療基礎設施改善的推動下，亞太地區苯二氮平類藥物產業將於 2024 年至 2032 年快速成長。此外，可支配收入水準的提高和對精神健康疾病的認知不斷提高，進一步促進了苯二氮平類藥物的使用。中國、印度和日本等國家可能處於該地區市場成長的前沿。

主要動向：按地區
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 11 章：公司簡介

AbbVie Inc.
Amneal Pharmaceuticals LLC.
Bausch Health Companies Inc.
Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc.
Hikma Pharmaceuticals PLC
Mylan N.V.
Novartis AG
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.

簡介目錄

Product Code: 8454

The Benzodiazepine Drugs Market is expected to garner a CAGR of 3.9% during 2024-2032, driven by rising cases of anxiety disorders, increasing awareness regarding mental health issues, and expanding geriatric population.

According to WHO, approximately 4% of the world's population is currently affected by anxiety disorders. Across the globe, there has been an increase in the incidence of anxiety disorders, including conditions like panic disorder and social anxiety disorder. This surge in prevalence is attributed to various factors, including societal stressors, economic uncertainties, and lifestyle changes. As individuals seek effective treatment options to manage their symptoms and improve their quality of life, the demand for benzodiazepine drugs, known for their anxiolytic properties, continues to escalate. Additionally, the availability of benzodiazepines as a first-line pharmacological intervention for anxiety disorders further contributes to their widespread usage, driving market growth in the pharmaceutical sector.

The Benzodiazepine Drugs industry is classified based on product, drug class, indication, route of administration, distribution channel, and region.

The Diazepam segment will record a healthy growth rate through 2032, owing to the anxiolytic, sedative, and muscle relaxant properties of diazepam and its usage in the management of anxiety disorders, muscle spasms, and alcohol withdrawal symptoms. Its versatility in treating various conditions, in line with its effectiveness and relatively low cost, has contributed to its significant market share. Moreover, the availability of generic formulations has further propelled the adoption of diazepam.

The insomnia segment will amass a decent benzodiazepine drugs market share by 2032, attributed to high stress levels, lifestyle changes, and the growing aging population. Benzodiazepines, including diazepam and other derivatives such as temazepam and lorazepam, are commonly prescribed for short-term management of insomnia due to their sedative-hypnotic properties. However, concerns regarding their potential for dependency and adverse effects have led to greater scrutiny and the exploration of alternative treatment modalities.

Asia Pacific Benzodiazepine Drugs Industry will grow rapidly from 2024 to 2032, driven by a large population base, increasing prevalence of mental health disorders, and improving healthcare infrastructure. Moreover, the rising disposable income levels and growing awareness regarding mental health ailments are further contributing to the uptake of benzodiazepine drugs. Countries such as China, India, and Japan could be at the forefront of market growth in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of anxiety disorders
  - 3.2.1.2 Rising geriatric population
  - 3.2.1.3 Increased incidence of insomnia
  - 3.2.1.4 Advancements in drug formulations
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Associated side effects
  - 3.2.2.2 Abuse potential and regulatory restrictions
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Million)

5.1 Key trends
5.2 Alprazolam
5.3 Diazepam
5.4 Lorazepam
5.5 Clonazepam
5.6 Temazepam
5.7 Oxazepam
5.8 Chlordiazepoxide
5.9 Other products

Chapter 6 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Million)

6.1 Key trends
6.2 Ultra-short acting
6.3 Short acting
6.4 Long acting

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Million)

7.1 Key trends
7.2 Anxiety
7.3 Insomnia
7.4 Alcohol withdrawal
7.5 Seizures
7.6 Other indications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Million)

8.1 Key trends
8.2 Oral
8.3 Parenteral
8.4 Other routes of administration

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

9.1 Key trends
9.2 Hospital pharmacy
9.3 Retail drug stores
9.4 Online pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

10.1 Key trends, by region
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa